JNJ-26489112
JNJ-26489112 is an anticonvulsant drug being developed by Johnson & Johnson for the treatment of epilepsy. JNJ-26489112 was designed as a successor to topiramate. It is expected to have fewer side effects than topiramate because it lacks activity against carbonic anhydrase. JNJ-26489112 is also being studied as a treatment for major depressive disorder. Its mechanism of action is unknown.
Link from a Wikipage to another Wikipage
primaryTopic
JNJ-26489112
JNJ-26489112 is an anticonvulsant drug being developed by Johnson & Johnson for the treatment of epilepsy. JNJ-26489112 was designed as a successor to topiramate. It is expected to have fewer side effects than topiramate because it lacks activity against carbonic anhydrase. JNJ-26489112 is also being studied as a treatment for major depressive disorder. Its mechanism of action is unknown.
has abstract
JNJ-26489112 is an anticonvuls ...... echanism of action is unknown.
@en
CAS number
871824-55-4
FDA UNII code
G1TI012DLT
PubChem
Wikipage page ID
42,193,326
page length (characters) of wiki page
Wikipage revision ID
963,904,201
Link from a Wikipage to another Wikipage
CAS number
ChemSpiderID
IUPAC name
-N-[methyl]sulfamide
@en
PubChem
11,616,111
SMILES
NSNC[C@H]1COC2=CC=CC=C2
@en
StdInChIKey
KXSAIQPPGSSNKX-ZETCQYMHSA-N
@en
UNII
G1TI012DLT
@en
wikiPageUsesTemplate
hypernym
comment
JNJ-26489112 is an anticonvuls ...... echanism of action is unknown.
@en
label
JNJ-26489112
@en